23Andme Holding Co.

07/21/2021 | Press release | Distributed by Public on 07/21/2021 09:47

A New 23andMe+ Report on HDL Cholesterol

Going Deeper on HDL

23andMe offers several reports that give customers insights into different heart-related conditions. For instance, there are reports on type 2 diabetes, familial hypercholesterolemia(an inherited form of high LDL cholesterol), and TTR-related hereditary amyloidosis, a genetic condition associated with cardiac and neurological problems.**

For those who want to go a little deeper, we offer 23andMe+,* an annual membership with 10+ exclusive reports and features delivered to you throughout the year. Among those reports are several heart-related conditions to explore. Along with reports on coronary artery disease, high blood pressure, atrial fibrillation, triglycerides, and LDL cholesterol, we recently added a new report on HDL cholesterol to 23andMe+. All are powered by 23andMe research.

This new report does not diagnoselow HDL cholesterol. Instead, it estimates the likelihood of developing low HDL based on a statistical model that considers more than 15,000 genetic markers associated with developing low HDL. The model also includes ethnicity and sex to calculate an estimate. The data used in the model comes from 23andMe customers who consented to participate in research.

Taking Action

Understanding more about your genetics can be a good first step in learning about your chances for heart disease. Remember to talk with your healthcare provider before making any major lifestyle changes. That said, maintaining a healthy weight, eating a diet that is low in saturated fat, and getting plenty of exercise can go a long way toward good heart health.

To learn more about 23andMe+ membership, gohere.

*10+ reports and features will be added annually from January to December.

***23andMe health predisposition reports include both reports that meet FDA requirements for genetic health risks and reports which are based on 23andMe research and have not been reviewed by the FDA. The test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person's overall risk of developing the disease. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. For important information and limitations regarding each genetic health risk report, visit